31.     Pétigny C, Dumont AA, Giguère H, Collette A, Holleran BJ, Iftinca M, Altier C, Besserer-Offroy É, Auger-Messier M, *Leduc R. (2022) Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation. Int J Mol Sci, 23(5):2502.

30.     Tran K, Sainsily X, Côté J, Coquerel D, Couvineau P, Saibi S, Haroune L, Besserer-Offroy É, Flynn-Robitaille J, Resua Rojas M, Murza A, Longpré JM, Auger-Messier M, Lesur O, Bouvier M, Marsault É, Boudreault PL, *Sarret P. (2021). Size-Reduced Macrocyclic Analogues of [Pyr ¹]-apelin-13 Showing Negative Gα ₁₂ Bias Still Produce Prolonged Cardiac Effects. J Med Chem, 65(1):531-551.

29.     Michaelian N, Sadybekov A, Besserer-Offroy É, Han GW, Krishnamurthy H, Zamlynny B, Fradera X, Siliphaivanh P, Prestland J, Spencer K, Soisson S, Popov P, Sarret P, Katritch V, *Cherezov V.(2021). Structural Insights on Ligand Recognition at the Human Leukotriene B4 Receptor 1. Nat Commun, 12:2971.

28.     Vivancos M, Fanelli R, Besserer-Offroy É, Beaulieu S, Chartier M, Resua-Rojas M, Mona CE, Previti S, Rémond E, Longpré JM, Cavelier F, *Sarret P. (2021). Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. Behav Brain Res; 405:113189.

27.    Sadybekov AA, Brouillette RL, Marin E, Sadybekov AV, Luginina A, Gusach A, Mishin A, Besserer-Offroy É, Longpré JM, Borshchevskiy V, Cherezov V, Sarret P, Katritch V. (2020). Structure-based virtual screening of ultra-large library yields potent antagonists for a lipid GPCR. Biomolecules. 10(12):1634. doi: 10.3390/biom10121634

26.    Besserer-Offroy É,Brouillette RL, Longpré JM, Sarret P. (2020). Assessing Gαq/15-signaling with IP-One: Single plate transfection and assay protocol for cell-based high-throughput assay. Bio-Protocol. 10(16):e3715. doi: 10.21769/BioProtoc.3715

25.    *Besserer-Offroy É,*Tétreault P, Brouillette RL, René A, Murza A, Fanelli R, Kirby K, Parent AJ, Dubuc I, Beaudet N, Côté J, Longpré JM, Martinez J, Cavelier F, Sarret P. (2020). Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8-13) analog. Data in Brief. 31C:105884. doi: 10.1016/j.dib.2020.105884

24.    *Tétreault P, *Besserer-Offroy É,Brouillette RL, René A, Murza A, Fanelli R, Kirby K, Parent AJ, Dubuc I, Beaudet N, Côté J, Longpré JM, Martinez J, Cavelier F, Sarret P. (2020). Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. European Journal of Pharmacology. 882C:173174. doi: 10.1016/j.ejphar.2020.173174

23.    *Brouillette RL, *˚Besserer-Offroy É, Mona CE, Chartier M, Lavenus S, Sousbie M, Belleville K, Longpré JM, Marsault É, Grandbois M, ˚Sarret P. (2020). Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain. Pharmacological Research. 155C:104750. doi: 10.1016/j.phrs.2020.104750

22.    Gusach A, Luginina A, Marin E, Brouillette RL, Besserer-Offroy É, Longpré JM, Ishchenko A, Popov P, Patel N, Fujimoto T, Stauch B, Ergasheva M, Romanovskaya D, Stepko A, Kovalev K, Shevtsov M, Gordeliy V, Han GW, Katritch V, Borshchevskiy V, *Sarret P, *Mishin A, *Cherezov V. (2019). Structural Basis of Ligand Selectivity and Disease Mutations in Cysteinyl Leukotriene Receptors. Nature Communications. 10:5573. doi: 10.1038/s41467-019-13348-2

21.     Boulkeroua C, Ayari H, Khalfaoui T, Lafrance M, Besserer-Offroy É, Ekindi N, Sabbagh R, Dumaine R, Lesur O, Sarret P, *Chraibi A. (2019). Apelin-13 regulates vasopressin-induced aquaporin-2 expression and trafficking in kidney collecting duct cells. Cell Physiol Biochem, 53(4):687-700. doi: 10.33594/000000165

20.     Luginina A, Gusach A, Marin E, Mishin A, Brouillette RL, Popov P, Shiryaeva A, Besserer-Offroy É, Longpré JM, Lyapina E, Ishchenko A, Patel N, Polovinkin V, Safronova N, Bogorodskiy A, Edelweiss E, Hu H, Weierstall U, Liu W, Batyuk A, Gordeliy V, Han GW, Sarret P, *Katritch V, *Borshchevskiy V, *Cherezov V. (2019.). Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs. Sci Adv, 5(10):eeax2518. doi: 10.1126/sciadv.aax2518

19.     *Besserer-Offroy É, Sarret P. (2019). Sending Out Biased Signals: An Appropriate Proposition For Pain? Douleur analg, 32(2), 108-110. doi: 10.3166/dea-2019-0065

18.     St-Pierre D, Cabana J, Holleran BJ, Besserer-Offroy É, Escher E, Guillemette G, Lavigne P, *Leduc R. (2018). Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms. Biochem Pharmacol, 154, 104-117. doi:10.1016/j.bcp.2018.04.021

17.     Lavenus S, Simard E, Besserer-Offroy É, Froelich U, Leduc R, *Grandbois M. (2018). Label-free cell signaling pathway deconvolution of Angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct agonist responses. Pharmacol Res, 136, 108-120. doi:10.1016/j.phrs.2018.06.027

16.     Sousbie M, Besserer-Offroy É, Brouillette R, Longpré JM, Leduc R, Sarret P, *Marsault É. (2018). In search of the optimal macrocyclization sites for neurotensin. ACS Med Chem Lett, 9(3), 227-232. doi:10.1021/acsmedchemlett.7b00500

15.     Sousbie M, Vivancos M, Brouillette R, Besserer-Offroy É, Longpré JM, Leduc R, Sarret P, *Marsault É. (2018). Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin 8-13. J Med Chem, 61(16), 7103-7115. doi:10.1021/acs.jmedchem.8b00175

14.     Besserer-Offroy É, Bérubé P, Côté J, Murza A, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Marsault É, *Sarret P. (2018). The hypotensive effect of activated apelin receptor iscorrelated with β-arrestin recruitment. Pharmacol Res, 131, 7-16. doi:10.1016/j.phrs.2018.02.032

13.     Fanelli R, Floquet N, Besserer-Offroy É, Delort B, Vivancos M, Longpré JM, Renault P, Martinez J, Sarret P, *Cavelier F. (2017). Use of Molecular Modeling to Design Selective-NTS2 Neurotensin Analogues. J Med Chem, 60(8), 3303-3313. doi:10.1021/acs.jmedchem.6b01848

12.     Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P, *Leduc R. (2017). Signaling signature of neurotensin receptor type 1 with endogenous ligands. Eur J Pharmacol, (805), 1-13. doi:10.1016/j.ejphar.2017.03.046

11.     Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, *Escher E. (2017). Agonist-Antagonist Transition in CXCR4 Ligands. J Pharmacol Toxicol Methods, 88(2), 170-171. doi:10.1016/j.vascn.2017.09.012

10.     Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, *Marsault É. (2017). Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. Org Biomol Chem, 15(2), 449-458. doi:10.1039/C6OB02247B

9.      Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault E, *Escher E. (2016). Structure Activity Relationship and Signaling of New Chimeric CXCR4 Agonists. J Med Chem, 59(16), 7512-7524. doi:10.1021/acs.jmedchem.6b00566

8.      *Thomas JB, Vivancos M, Giddings AM, Wiethe RW, Warner KR, Murza A, Besserer-Offroy É, Longpré JM, Runyon SP, Decker AM, Gilmour BP, Sarret P. (2016). Identification of 2-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13, 7]decane-2-carboxylic acid (NTRC-844) as a selective antagonist for the Rat Neurotensin receptor type 2. ACS Chem Neurosci, 7(9), 1225-1231. doi:10.1021/acschemneuro.6b00097

7.      Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault E, *Escher E. (2016). Design, Synthesis, and Biological Evaluation of Novel CXCR4 Inverse Agonists. Org Biomol Chem, 14(43), 10298-10311. doi:10.1039/C6OB01484D

6.      Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, Longpre JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, *Marsault E. (2016). Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem, 59(7), 2962-2972. doi:10.1021/acs.jmedchem.5b01549

5.      Hapau D, Rémond E, Fanelli R, Vivancos M, René A, Côté J, Besserer-Offroy É, Longpré JM, Martinez J, Zaharia V, Sarret P, *Cavelier F. (2016). Stereoselective synthesis of β-(5-arylthiazolyl) α-amino acids and use in neurotensin analogues. Euro J Org Chem, 2016(5), 1017-1024. doi:10.1002/ejoc.201501495

4.      Murza A, Besserer-Offroy É, Côté J, Bérubé P, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Sarret P, *Marsault E. (2015). C-terminal modifications of apelin-13 significantly change ligand binding, receptor signaling and hypotensive action. J Med Chem, 58(5), 2431-2440. doi:10.1021/jm501916k

3.      Besserer-Offroy É, Fanelli R, René A, Côté J, Tétrault P, Collerette-Tremblay J, Longpré JM, Leduc R, Martinez J, Sarret P, *Cavelier F. (2015). Synthesis, in vitro and in vivo characterization of (L)-(trimethylsilyl)alanine containing neurotensin analogues. J Med Chem, 58(19), 7785-7795. doi:10.1021/acs.jmedchem.5b00841

2.      Demeule M, Beaudet N, Régina A, Besserer-Offroy É, Murza A, Tétreault P, Belleville K, Ché C, Larocque A, Thiot C, Béliveau R, Longpré JM, Marsault É, Leduc R, Lachowicz JE, Gonias SL, Castaigne JP, Sarret P. (2014). Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Invest, 124(3), 1199-1213. doi:10.1172/JCI70647

1.      Murza A, Parent A, Besserer-Offroy É, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, *Marsault É. (2012). Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. ChemMedChem, 7(2), 318-325. doi:10.1002/cmdc.201100492